Ilico Genetics is developing a methylated DNA-based molecular test that detects early-stage gastric cancer through a simple blood sample, even in asymptomatic patients. This test enables dynamic monitoring of tumor presence over time, significantly reducing treatment costs by 90% compared to advanced-stage interventions.
Funding
$460K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Gastric cancer, the fifth most common cancer worldwide, often presents with subtle symptoms easily mistaken for common digestive issues, leading to late-stage diagnoses. Current diagnostic methods lack the sensitivity to detect the disease in its early, asymptomatic stages, resulting in higher treatment costs and reduced survival rates.
Solution
Ilico Genetics is developing a blood-based molecular test for the early detection and monitoring of gastric cancer. The test utilizes methylated DNA biomarkers to identify the presence of early-stage tumors, even before symptoms appear. By enabling earlier detection, the test facilitates timely intervention and dynamic monitoring of tumor presence, potentially reducing treatment costs and improving patient outcomes. The non-invasive nature of the blood test allows for convenient and frequent screening, addressing a critical need for accessible and effective gastric cancer detection.
Target Audience
The primary target audience includes healthcare providers, particularly gastroenterologists and oncologists, as well as individuals at high risk for gastric cancer, such as those with a family history or H. pylori infection.
Features
- Methylated DNA-based assay for high sensitivity and specificity in early-stage detection
- Non-invasive blood sample collection for easy and frequent screening
- Quantitative results for dynamic monitoring of tumor presence over time
- Timely results to prioritize at-risk patients for further evaluation and treatment
- Potential for significant reduction in treatment costs compared to advanced-stage interventions